Genetic study of neurexin and neuroligin genes in Alzheimer's disease

Manuscript Number: 

12-2257R2

Author(s): 
Carmen Antunez, Mercè Boada, Evaristo Fernandez, Javier Gayan, Antonio Gonzalez-Perez, Jesus Lopez-Arrieta, Juan Marin, Amalia Martinez-Mir, Reposo Ramirez-Lorca, Luis M. Real, Agustín Ruíz, Maria Eugenia Saez, Francisco G. Scholl

Disclosures

Carmen Antunez

  • Nothing to Disclose

Mercè Boada

  • Consulting Fees:
    2011 Bayer: Expert meeting, Barcelona / Neuroptix: Advisory Board, Paris / Bayer: Expert Panel Discussion, Paris / Avid: Avid's Clinical Utility Advisory Board, Amsterdam / Janssen/Pfizer: ARIA Educational Advisory Committee, New Jersey / Flowlab: Advisory Board, Barcelona. 2012 Nutricia: Expert Meeting, Stockholm / Lilly: AD European Advisory Board, Londres / Lilly: AD European Advisory Board, Paris / Neuroptix: Clinical Advisory Board, Vancouver / Janssen/Pfizer: ARIA Educational Advisory Committee, Vancouver / Lilly: AD European Advisory Board, Nice / Grifols: Advisory Board, Los Angeles / Esteve/Novartis: Alzhima Council-Advisory Board, Barcelona.
    Lecture Fees:
    2011 Esteve: ARC, Barcelona / Janssen: Dementia, Málaga / Janssen: Neo, Madrid 2012 Inst. Roche: Seminario Prensa, Baiona / Nutricia: Souvenaid, Barcelona / Grifols: Ambar, Barcelona

Evaristo Fernandez

  • Nothing to Disclose

Javier Gayan

  • Nothing to Disclose

Antonio Gonzalez-Perez

  • Nothing to Disclose

Jesus Lopez-Arrieta

  • Nothing to Disclose

Juan Marin

  • Nothing to Disclose

Amalia Martinez-Mir

  • Nothing to Disclose

Reposo Ramirez-Lorca

  • Nothing to Disclose

Luis M. Real

  • Equity:
    I am shareholder in Neocodex SL

Agustín Ruíz

  • Equity:
    Stocks in Neocodex SL and Oxigene Inc
    Patents/Royalties
    I am co-author of several world patents on Neurodegenerative genetic markers (but unrelated to this work). Neocodex is the owner.

Maria Eugenia Saez

  • Nothing to Disclose

Francisco G. Scholl

  • Nothing to Disclose